Oncology Central

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era

0

Lung cancer is the leading cause of cancer-related mortality worldwide in both sexes, expected to account, in the near future, for more than 30% of all cancer-related deaths. Recently, improvements in the systemic therapy of non-small-cell lung cancer according to histology and tumor molecular characteristics led to a progressive prolongation of survival, more clinically meaningful in selected groups of patients with tumors harboring specific genomic alterations.

To view restricted content, please:
Share:

Leave A Comment